koselugo
astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antineoplastische middelen - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.
metaperex 400 ie zachte capsules
tocoferol, d-alfa (e 307) 280 mg/stuk ; samenstelling overeenkomend met tocoferol, d-alfa (e 307) 400 ie/stuk - capsule, zacht - gelatine (e 441) ; glycerol (e 422) ; sojaboonolie
metaperex 400 ie zachte caps.
kora corporation t/a kora healthcare ltd. - dl-alfa-tocoferol 280 mg - capsule, zacht - tocopherol (vit e)
cibinqo
pfizer europe ma eeig - abrocitinib - dermatitis, atopic - andere dermatologische preparaten - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
sunitinib krka 12,5 mg harde caps.
krka d.d. novo mesto d.d. - sunitinibmalaat 16,71 mg - eq. sunitinib 12,5 mg - capsule, hard - 12,5 mg - sunitinibmalaat 16.71 mg - sunitinib
sunitinib krka 25 mg harde caps.
krka d.d. novo mesto d.d. - sunitinibmalaat 33,41 mg - eq. sunitinib 25 mg - capsule, hard - 25 mg - sunitinibmalaat 33.41 mg - sunitinib
sunitinib krka 50 mg harde caps.
krka d.d. novo mesto d.d. - sunitinibmalaat 66,83 mg - eq. sunitinib 50 mg - capsule, hard - 50 mg - sunitinibmalaat 66.83 mg - sunitinib
sunitinib teva 12.5 mg harde caps.
teva b.v. - sunitinib 12,5 mg - capsule, hard - 12,5 mg - sunitinib 12.5 mg - sunitinib
sunitinib teva 25 mg harde caps.
teva b.v. - sunitinib 25 mg - capsule, hard - 25 mg - sunitinib 25 mg - sunitinib
sunitinib teva 37.5 mg harde caps.
teva b.v. - sunitinib 37,5 mg - capsule, hard - 37,5 mg - sunitinib 37.5 mg - sunitinib